EVT 801
Alternative Names: EVT-801Latest Information Update: 07 May 2024
At a glance
- Originator Sanofi
- Developer Evotec SE; Sanofi
- Class Antineoplastics; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Cancer
Most Recent Events
- 01 May 2024 Efficacy and adverse event data from a phase I trial in Solid tumours released by Kazia Therapeutics
- 07 Apr 2024 Pharmacodynamics data from a phase I trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Kaiza Therapeutics plans a phase II trial for Solid tumors in 2024